PMC Capital Acquires the Assets of Ransom & Randolph Company from Dentsply Sirona

February 2, 2021

PMC Capital notes that Ransom & Randolph Company, is a leading mission-critical manufacturer and supplier of specialty consumables to the global investment casting industry, serving aerospace, defense, industrial gas turbine, automotive, commercial, jewelry, dental, and art casting markets from Dentsply Sirona, Inc.

Financial terms of the transaction were not disclosed.

The divestment of Ransom & Randolph is part of Dentsply Sirona’s strategy to focus on its core business.

“We are extremely thrilled that this transaction creates an opportunity from which both sides will benefit. As Ransom & Randolph looks forward to the future, the roadmap will be to execute a growth model which includes strategic acquisition and organic growth,” says Michel Tamer, Managing Partner of PMC Capital.

“As an independent business, Ransom & Randolph will strengthen its focus on our industrial foundry, jewelry and dental lab customer base, while also remaining an important partner to Dentsply Sirona. The R&R team and I are eager to serve our customers in new and exciting ways,” says Daniel Nixon, President of Ransom & Randolph.

Founded in 1872, Ransom & Randolph is dedicated to advancing the global investment casting industry. Ransom & Randolph has provided foundries, dental labs, and jewelers with extensive process knowledge, exceptional technical expertise and innovative product technology since the 1800s. By coupling revolutionary product developments with experienced staff, manufacturing and warehousing facilities worldwide, Ransom & Randolph successfully helps customers become casting industry leaders.

CriticalPoint Partners, LLC served as Dentsply Sirona’s exclusive financial advisor for the transaction. 

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.
Vicarious Surgical added Philip Liang and Ric Fulop to their Board of Directors. 

By using this website you agree to accept Medical Device News Magazine Privacy Policy